Rucaparib (Rubraca, pharma&) is indicated 'as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy'.
The dosage schedule is available in the summary of product characteristics for rucaparib.
The list price for rucaparib is £3,562.00 per 60‑tablet pack of 300 mg, 250 mg or 200 mg tablets (excluding VAT; BNF online, accessed January 2025). The company estimates that the average cost per year of rucaparib is £105,869 (estimated from the deterministic base-case economic analysis using the list price).
The company has a commercial arrangement. This makes rucaparib available to the NHS with a discount. The size of the discount is commercial in confidence.